Dexamethasone/levofloxacin

Dexamethasone/levofloxacin
Combination of
DexamethasoneCorticosteroid
LevofloxacinAnti-infective
Clinical data
Trade namesLevodexa
Routes of
administration		Eye drops
ATC code
Legal status
Legal status

Dexamethasone/levofloxacin, sold under the brand name Levodexa, is a fixed-dose combination medication used for the prevention and treatment of inflammation, and the prevention of infection, associated with cataract surgery.[1][3] It contains dexamethasone, a corticosteroid; and levofloxacin, an anti-infective.[1]

It was approved for medical use in Canada in December 2023.[1]

Medical uses

Dexamethasone/levofloxacin is indicated for the prevention and treatment of inflammation, and the prevention of infection, associated with cataract surgery in adults.[1]

References

  1. ^ a b c d e "Regulatory Decision Summary for Levodexa". Drug and Health Products Portal. 12 December 2023. Retrieved 2 April 2024.
  2. ^ "Levodexa Product information". Health Canada. 12 December 2023. Retrieved 2 April 2024.
  3. ^ Rizzo S, Gambini G, De Vico U, Rizzo C, Kilian R (February 2022). "A One-Week Course of Levofloxacin/Dexamethasone Eye Drops: A Review on a New Approach in Managing Patients After Cataract Surgery". Ophthalmology and Therapy. 11 (1): 101–111. doi:10.1007/s40123-021-00435-1. PMC 8770779. PMID 34936061.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.